219 results on '"Maribavir"'
Search Results
2. A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
3. A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
4. A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
5. A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
6. A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
7. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients
8. Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
9. Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.
10. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
11. Effect of Food, Crushing of Tablets, and Antacid Coadministration on Maribavir Pharmacokinetics in Healthy Adult Participants: Results From 2 Phase 1, Open‐Label, Randomized, Crossover Studies.
12. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
13. Individualizing Treatment for CMV with UL97 del597-599 Mutation: Beyond Unusual Response to a Lower Ganciclovir Dose Increase
14. Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infection
15. Maribavir Food-Effect Study in Healthy Adults Participants
16. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
17. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study.
18. Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
19. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
20. EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS.
21. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
22. Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.
23. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
24. Case Report: Approaches for managing resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplantation recipients
25. A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
26. Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir
27. Anti-CMV therapy, what next? A systematic review.
28. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update
29. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient
30. A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants
31. [Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy]
32. Anti-CMV therapy, what next? A systematic review
33. New Treatment Options for Refractory/Resistant CMV Infection.
34. New Treatment Options for Refractory/Resistant CMV Infection.
35. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
36. Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
37. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
38. New Treatment Options for Refractory/Resistant CMV Infection
39. Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open‐Label Study.
40. Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
41. Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
42. Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
43. Study of SHP620 (Maribavir) in Healthy Adults
44. Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
45. Maribavir for Prevention of CMV After Stem Cell Transplants
46. New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease
47. Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
48. New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.
49. A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
50. Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.